[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esotropia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esotropia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,80,107,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100629093","phase-3-a-randomized-trial-of-botulinum-toxin-a-vs-strabismus-surgery-for-esotropia-10-to-30pd-100629093",false,"NCT07470164","A Randomized Trial of Botulinum Toxin A vs Strabismus Surgery for Esotropia >10 to ≤30PD","ETS4","1. A constant or intermittent ET needing intervention with BTX-A or surgery in the judgement of the investigator meeting one of the criteria below:\n\n   Infantile Esotropia (IET)\n   * Onset prior to six months of age by parental history.\n   * Angle measuring \\>10 to ≤ 30 PD by PACT in the primary position at distance fixation on an accommodative target.\n\n   Acquired Non-accommodative Esotropia (ANAET)\n   * Onset after six months of age by parental history\n   * Angle decreases less than 10 PD by PACT in the primary position at distance fixation with hyperopic correction.\n   * Residual angle measuring \\>10 to ≤ 30 PD by SPCT in the primary position at distance fixation on an accommodative target.\n\n   Acquired Partially Accommodative Esotropia (APAET)\n   * Onset after six months of age by parental history\n   * Angle decreases 10 PD or more by PACT in the primary position at distance fixation with correction.\n   * Residual angle measuring \\>10 to ≤ 30 PD by SPCT in the primary position at distance fixation on an accommodative target.\n2. Age at enrollment:\n\n   * For IET: \\> 4 months to \\\u003C17 years old\n   * For ANAET or APAET: \\>6 months to \\\u003C17 years old\n3. No myopia ≥ 6.00D SE\n4. Current Spectacle Correction at Time of Enrollment\n\n   * For IET: No spectacle wear prior to enrollment.\n   * For ANAET or APAET: Must be wearing spectacles if significant refractive error as defined below based upon a cycloplegic refraction within 6 months of enrollment. If no significant refractive error, spectacles are at investigator discretion. In either case full hyperopic correction by cycloplegia worn for at least 2 weeks.\n5. Requirements for Spectacle Correction (if worn)\n\n   * If myopia is \\\u003C 6.00D SE, then full CR must be worn for at least 2 weeks.\n   * For children \\\u003C 5 years of age who have significant hyperopic refractive error (CR ≥ +2.50D SE), full hyperopic correction, determined by CR must have been worn for at least 2 weeks.\n   * For children ≥ age 5 years, with significant hyperopic refractive error who are unable to tolerate correction of full CR due to blur, then maximally-tolerated hyperopic correction determined both with and without cycloplegia is prescribed and must be worn for at least 2 weeks.\n   * For patients who do not have significant hyperopic refractive error (CR \\\u003C +2.50D SE), whether to prescribe spectacles is at investigator discretion. However, if the investigator elects to prescribe spectacles, the full tolerated hyperopic correction determined with and without cycloplegia must have been worn for at least 2 weeks.\n6. Parent or legal guardian available for follow-up, has home phone (or access to phone), and willing to be contacted by Jaeb Center staff\n7. Gestational age \\> 34 weeks\n8. Birth weight \\> 1500 grams\n9. No use of atropine within the last two weeks.\n10. No history of CNS disease (e.g., IVH, PVL, meningitis, developmental abnormalities of the brain, hydrocephalus, cerebral palsy, hypoxic ischemic encephalopathy)\n11. No significant developmental delay in the investigator's judgment (isolated speech delay excepted)\n12. No limitation of abduction consistent with paralytic or restrictive myopathy (minor limitation of abduction due to cross fixation is acceptable)\n13. No craniofacial malformation affecting the orbits\n14. No prior BTX-A injection for strabismus\n15. No prior extraocular muscle surgery or intraocular surgery\n16. No structural ocular abnormalities (e.g., media opacity, optic atrophy, optic nerve hypoplasia, retinal detachment)\n17. No immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is investigative site personnel directly affiliated with this study or who is an employee of the Jaeb Center for Health Research.","ALL","4 Months","17 Years",{"count":20,"type":21},244,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Childhood esotropia (ET) is a common cause of visual disability, and its early management is critical for optimal visual and developmental outcomes.\n\nThe proposed study addresses a need to evaluate botulinum toxin A (BTX-A) as a less invasive, cost-effective alternative to incisional strabismus surgery. If BTX-A is demonstrated to be non-inferior to incisional strabismus surgery in treating ET \\>10 to ≤30PD, this could reduce surgical and anesthesia-related risks in infants, lower the economic burden on families and healthcare systems, and reduce disparities in access to care, particularly in underserved settings where surgical resources are limited.",[27],"Esotropia",[29,30,31,32],"strabismus","pediatric","botox","botulinum toxin a","NOT_YET_RECRUITING","2026-03-31",{"date":36,"type":37},"2026-04-06","ACTUAL",{"date":39,"type":21},"2027-01",{"date":41,"type":21},"2030-01",{"name":43,"class":44},"Jaeb Center for Health Research","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100627283","risk-factors-and-surgical-outcomes-of-strabismus-reoperation-100627283","NCT07446621","Risk Factors And Surgical Outcomes Of Strabismus Reoperation","Risk Factors And Surgical Outcomes Of Strabismus Reoperation: A Clinical Study","RSOR","Inclusion Criteria:\n\n* Patients diagnosed with horizontal strabismus (esotropia or exotropia).\n\n  * Patients undergoing repeat surgery for correction of residual, recurrent, undercorrected, or overcorrected horizontal strabismus.\n  * Availability of sufficient medical records documenting previous strabismus surgery.\n  * Ability to attend scheduled postoperative follow-up visits.\n  * Written informed consent obtained from the patient or legal guardian.\n\nExclusion Criteria:\n\n* Combined vertical and horizontal strabismus.\n\n  * Paralytic strabismus.\n  * Restrictive strabismus.\n  * Strabismus associated with neurological or syndromic conditions.\n  * Patients with incomplete or insufficient documentation of previous surgical procedures.\n  * Patients unwilling or unable to complete follow-up.",{"count":54,"type":21},62,[56],"NA","Horizontal strabismus, commonly known as inward or outward deviation of the eyes, is a frequent eye condition that may require surgical correction. Although the first surgery is often successful, some patients develop residual or recurrent eye misalignment and require a second operation (reoperation).\n\nThis study aims to identify the clinical and surgical factors that may increase the risk of undercorrection, overcorrection, or recurrence after the first surgery. It also evaluates the outcomes and success rate of repeat surgery in patients with horizontal strabismus.\n\nPatients undergoing reoperation will receive a complete ophthalmological examination before surgery. The surgical plan will be individualized based on previous surgical history and current eye findings. All procedures will be performed under general anesthesia by the same surgeon. Participants will be followed for three months after surgery to assess eye alignment, movement, and possible complications.\n\nThe results of this study may help improve surgical planning and predict which patients are at higher risk of requiring additional surgery in the future.",[59,27,60],"Strabismus","Exotropia",[62,63,64,65,66,67,68,69],"Horizontal strabismus","Strabismus reoperation","Recurrent strabismus","Ocular alignment","Prism diopters","Paediatric strabismus surgery","Orthotropia","Ocular motility","2026-03-06",{"date":72,"type":37},"2026-03-09",{"date":74,"type":21},"2026-03",{"date":76,"type":21},"2027-07",{"name":78,"class":44},"Assiut University",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":79},"100563890","vision-therapy-versus-prism-treatment-in-small-angle-acute-acquired-concomitant-esotropia-100563890","NCT06622044","Vision Therapy Versus Prism Treatment in Small-angle Acute Acquired Concomitant Esotropia","Accommodation and Vergence Exercises Versus Prism Treatment for Small-angle Acute Acquired Concomitant Esotropia","Inclusion Criteria:\n\n1. Aged 10-40 years (including 10 years and 40 years);\n2. Best-corrected visual acuity no worse than 20\u002F20 for both eyes;\n3. Deviation angle less than 15 prism diopters (including 15 prism diopters);\n\nExclusion Criteria:\n\n1. Organic eye diseases;\n2. Lesions of the brain;\n3. Receiving esotropia therapy(including surgery and prism treatment)\n4. Devation angle reducing more than 10 prism diopters after refractive correction","10 Years","40 Years",{"count":90,"type":21},100,[56],"This is a single-center, randomized controlled clinical trial to compare the effectiveness of vision therapy and prism wearing for the treatment of small-angle acute acquired concomitant esotropia.",[27],[95,96],"Vision Therapy","Acute Acquired Concomitant Esotropia","RECRUITING","2025-12-02",{"date":100,"type":37},"2025-12-09",{"date":102,"type":37},"2024-09-07",{"date":104,"type":21},"2026-12-07",{"name":106,"class":44},"Eye & ENT Hospital of Fudan University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":88,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":79},"100571026","accommodation-related-visual-training-combined-with-transcranial-electrical-stimulation-versus-visual-training-alone-for-the-treatment-of-accommodation-dysfunction-100571026","NCT06714890","Accommodation-Related Visual Training Combined with Transcranial Electrical Stimulation Versus Visual Training Alone for the Treatment of Accommodation Dysfunction","A Single-center, Prospective, Randomized Controlled Trial Evaluating Accommodation-related Visual Training Combined with Transcranial Electrical Stimulation Versus Accommodation-related Visual Training Alone for the Treatment of Accommodation Dysfunction","Inclusion Criteria:\n\n1. Inclusion criteria for small-angle acute concomitant esotropia: clinical diagnosis of acute aquired concomitant esotropia; strabismus angle ≤ 15PD; age 18 \\\u003C age \\\u003C 40; best corrected visual acuity of both eyes ≥ 1.0.\n2. Inclusion criteria for presbyopia: clinical diagnosis of presbyopia; best corrected visual acuity of both eyes ≥ 1.0.\n\nExclusion Criteria:\n\n1. no history of other eye diseases or eye surgeries\n2. no history of neuropsychiatric diseases for the individual or relatives\n3. no head injuries or surgeries\n4. no history of epilepsy or stroke\n5. no metal implants in the body\n6. no claustrophobia, no metal implants in the body (fracture fixation nails, pacemakers, etc.)\n7. pregnancy","18 Years",{"count":90,"type":21},[56],"This is a single-center, randomized controlled trial to compare the effectiveness of transcranial electrical stimulation combined with visual training with visual training alone for the treatment of accommodation disorder patients.",[119,27],"Presbyopia",[96,119,121,122,123],"Accommodation Disorder","Transcranial Electrical Stimulation","Visual Training","2024-12-03",{"date":126,"type":37},"2024-12-05",{"date":128,"type":21},"2024-12-31",{"date":130,"type":21},"2026-12-31",{"name":106,"class":44},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":79},"100571025","botulinum-toxin-injection-versus-prism-treatment-in-small-angle-acute-acquired-concomitant-esotropia-100571025","NCT06714877","Botulinum Toxin Injection Versus Prism Treatment in Small-angle Acute Acquired Concomitant Esotropia","A Single-center, Prospective, Randomized Controlled Trial Evaluating Type a Botulinum Toxin Injection and Prism Therapy for the Treatment of Acute Acquired Concomitant Esotropia","Inclusion Criteria:\n\n1. acute acquired concomitant esotropia diagnosis (sudden onset of esotropia or diplopia, no significant change in the degree of strabismus in each eye position, and no limitation in eye movement)\n2. strabismus angle ≤ 25PD\n3. best corrected visual acuity of both eyes ≥ 1.0\n4. intracranial disease is excluded by cranial CT or magnetic resonance imaging\n\nExclusion Criteria:\n\n1. reduction of strabismus angle by more than 10 prism diopters after refractive correction\n2. history of other ocular diseases or ocular surgeries\n3. presence of organic brain lesions or systemic diseases",{"count":90,"type":21},[56],"This is a single-center, prospective, randomized controlled trial evaluating type A botulinum toxin injection and prism therapy for the treatment of small-angle acute acquired concomitant esotropia.\n\nSpecific Aim 1 (Primary): To compare the reduction of deviation angle and improvement of diplopia symptoms between botulinum toxin injection and prism therapy for the treatment of small-angle acute acquired concomitant esotropia.\n\nSpecific Aim 2 (Secondary): To compare the improvement of visual functions between botulinum toxin injection and prism therapy for the treatment of small-angle acute acquired concomitant esotropia.",[27],[96,144,145],"Treatment","Botulinum Toxin Injection",{"date":126,"type":37},{"date":148,"type":21},"2024-12-10",{"date":150,"type":21},"2026-12-10",{"name":106,"class":44}]